Sullivan & Cromwell Reps Valeant In $5.7B Cephalon Bid
Neurology and dermatology pharmaceutical developer Valeant offered $73 for each share in cash — nearly 30 percent more than Cephalon's 30-day trading average. Valeant also plans to run a slate of its own nominees to Cephalon's board of directors.
“We have taken a close look at Cephalon's business and believe we put forward a very compelling offer for Cephalon's stockholders,” Valeant CEO...
To view the full article, register now.